AOTI, INC. - Results for the year ended 31 December 2025

AOTI Inc’s latest investor update highlights solid financial results and a compelling growth strategy despite US healthcare headwinds. FY2025 revenue rose 14% to $66.5 million, with underlying growth of 15%, while adjusted EBITDA reached $7.5 million and margins of 11.3%, reflecting continued investment in market access and commercial expansion. The company’s clinically proven TWO2 therapy drives improved patient outcomes and cost efficiencies, underpinning its competitive positioning in the advanced wound care market. AOTI continues to expand its reimbursement footprint, securing Medicaid provider IDs across 19 states and gaining payer endorsements, while addressing temporary challenges in Arizona to stabilise cash flow. Looking ahead, FY2026 is expected to be a transitional year with modest reported revenue growth but stronger underlying performance. A key catalyst remains potential CMS Medicare coverage, which could significantly expand the addressable market and accelerate revenue growth, margins, and long-term value creation.